Results 131 to 140 of about 34,405 (271)
The Krüppel-like factor 15-NFATc1 axis ameliorates podocyte injury: a novel rationale for using glucocorticoids in proteinuria diseases [PDF]
Caoshuai Dou +17 more
openalex +1 more source
Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment [PDF]
Qingsi Wu +7 more
openalex +1 more source
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li +5 more
wiley +1 more source
ULTRASTRUCTURAL CHANGES OF PODOCYTES OF THE SINGLE KIDNEY AFTER REMOVAL OF THE CONTRALATERAL ONE
В. І. Півторак +1 more
openalex +2 more sources
Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy [PDF]
Yuxiang Liu +12 more
openalex +1 more source
Modulators of Diacylglycerol Kinase Activity: A Review of Advances and Challenges
ABSTRACT Catalyzing the conversion of diacylglycerol (DAG) in phosphatidic acid (PA), diacylglycerol kinases (DGKs) play a pivotal role in all the physiological processes modulated by these two bioactive lipids, such as lipid metabolism and immune regulation.
Luisa Racca +2 more
wiley +1 more source
Fibroblast‐specific palladin drives kidney fibrosis via MRTF–SRF signaling
Abstract Fibrosis is a common end‐stage pathway of progressive chronic kidney diseases. Previously we demonstrated that myocardin‐related transcription factor (MRTF)–serum response factor (SRF) signaling drives the expression of fibrosis‐related molecules through actin cytoskeleton dynamics in renal fibroblasts.
Naoki Yamamoto +27 more
wiley +1 more source
IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda +13 more
wiley +1 more source

